Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Sequential Progestin for EIN
NCT00503581Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Jul 2007
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of megestrol in Endometrial intraepithelial neoplasia (EIN) (3 arms), sponsored by GOG Foundation. Primary endpoint: Frequency of Complete Remission by Central Pathology Review up to 12 months. Started Jul 2007; status: terminated.
02
Drugs
megestrol
03
Conditions
Endometrial intraepithelial neoplasia (EIN)
Beyond the preview
Go deeper on NCT00503581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503581.